Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MYNZ
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.21
N/A
-0.02
vs -0.01
Q4.21
N/A
-1.30
vs -0.01
Q2.22
N/A
-0.97
vs -0.02
Q4.22
N/A
-18.00
vs -1.30
Q2.23
N/A
-15.60
vs -0.97
Q4.23
N/A
-9.60
vs -18.00
Q2.24
N/A
-15.60
vs -15.60
Q3.24
N/A
-5.20
vs NA
Q4.24
N/A
-3.60
vs -9.60
Sales Growth
YoY
Current
Estimates
Q2.21
+69%
417.3K vs 246.8K
Q4.21
-35%
160K vs 246.8K
Q2.22
-33%
278.5K vs 417.3K
Q4.22
+57%
251.4K vs 160K
Q2.23
+80%
500.2K vs 278.5K
Q4.23
-15%
214.8K vs 251.4K
Q2.24
+4%
520.8K vs 500.2K
Q3.24
NA
600K vs NA
Q4.24
+147%
531.2K vs 214.8K
Return on Equity
QoQ
Q2.21
+10%
0.1
vs 0.11
Q4.21
-180%
-1.80
vs 0.1
Q2.22
-58%
-0.58
vs -1.80
Q4.22
-89%
-0.89
vs -0.58
Q2.23
-256%
-2.56
vs -0.89
Q4.23
-160%
-1.60
vs -2.56
Q2.24
+266%
2.66
vs -1.60
Q4.24
NA
NA
vs 2.66
Institutionnal Ownership
QoQ
Q4.22
6
6
vs 4
50%
Q1.23
6
6
vs 6
NA
Q2.23
9
9
vs 6
50%
Q3.23
8
8
vs 9
-11%
Q4.23
11
11
vs 8
38%
Q1.24
12
12
vs 11
9%
Q2.24
9
9
vs 12
-25%
Q3.24
11
11
vs 9
22%
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
9 hours ago
Relative Strength
MYNZ
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
NASDAQ
Unprofitable
Unprofitable
0.02 ( 0.63%)
After-hours 3.17$
-0.06 (-1.71%)
Relative Strenght
Volume Buzz
-82%
Earning Acce
No
Dist 52w H.
61%Forecast
112%2025-Revenue
80%2025-EPS
89%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available